Z Liu, Z Lin, F Cao, M Jiang, S Jin,
Y Cui, YN Niu - BMC urology, 2022 - Springer
Abstract Background 5-α reductase inhibitors (5-ARIs) are first-line drugs for managing
benign prostatic hyperplasia (BPH). Unfortunately, some patients do not respond to 5-ARI …